- •Adherence to daily care by pediatric CF patients can be a challenge.
- •Increased daily ACT in school was associated with fewer pulmonary exacerbations.
- •Unique collaboration between CF care center and schools improved adherence.
Adherence to airway clearance therapy (ACT) in pediatric cystic fibrosis (CF) patients is reported to be below 50% and inability to sustain daily care is linked to poor health outcomes7,8,9. Through a collaboration between a CF care center and several schools, we hypothesized that ACT completed at school by pediatric CF patients will improve lung function while decreasing pulmonary exacerbations (PEx), days of antibiotics (abx) and hospitalizations.
This was a retrospective case-control study at a single CF care center consisting of 50 CF patients age < 18 at time when data was recorded (2012–2020). The case group used high-frequency chest wall oscillation or positive expiratory pressure devices at school for at least 1 year after self-reported or physician identified inadequate use at home. Lung function and measures of healthcare utilization were collected.
In the case group (n = 14), paired t-tests showed that after initiation of ACT at school, there were significant reductions in PEx requiring IV or PO abx (P = 0.010), total days of abx (P = 0.032), and visits to the CF care center (P = 0.037). There was no change in these outcomes in the matched control group (n = 36).
This is the first known study to highlight an initiative between a CF care center and schools which utilized airway clearance devices at school to ensure pediatric CF patients completed ACT. Through increased adherence, this relationship was associated with improved health outcomes. Use of alternative strategies may help patients with CF sustain adequate airway clearance.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Cystic Fibrosis
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Cystic fibrosis: pathophysiology of lung disease.Semin Respir Crit Care Med. 2019; 40: 715-726https://doi.org/10.1055/s-0039-1694021
- Background and Epidemiology.Pediatr Clin N Am. 2016; 63: 567-584https://doi.org/10.1016/j.pcl.2016.04.001
- CFTR modulator therapies - Effect on life expectancy in people with cystic fibrosis.Paediatr Respir Rev. 2022; 42: 3-8https://doi.org/10.1016/j.prrv.2020.05.002
- Cystic fibrosis pulmonary guidelines: airway clearance therapies.Respir Care. 2009; 54: 522-537
- Airway clearance techniques for cystic fibrosis: an overview of Cochrane systematic reviews.Cochrane Database Syst Rev. 2019; 1CD011231https://doi.org/10.1002/14651858.CD011231.pub2
- Objective measures of vest therapy adherence among pediatric subjects with cystic fibrosis.Respir Care. 2020; 65: 1831-1837https://doi.org/10.4187/respcare.07421
- Adherence to treatment in children and adolescents with cystic fibrosis: a cross-sectional, multi-method study investigating the influence of beliefs about treatment and parental depressive symptoms.BMC Pulm Med. 2015; 1543https://doi.org/10.1186/s12890-015-0038-7
- Objective versus self-reported adherence to airway clearance therapy in cystic fibrosis.Respir Care. 2019; 64 (Feb): 176-181https://doi.org/10.4187/respcare.06436
- Longitudinal association between medication adherence and lung health in people with cystic fibrosis.J Cyst Fibros. 2011; 10: 258-264https://doi.org/10.1016/j.jcf.2011.03.005
- Strategies to optimize treatment adherence in adolescent patients with cystic fibrosis.Adolesc Health Med Ther. 2016; 7: 117-124https://doi.org/10.2147/AHMT.S95637
- School-based supervised therapy programs to improve asthma outcomes: current perspectives.J Asthma Allergy. 2018; 11 (Aug 29): 205-215https://doi.org/10.2147/JAA.S147524
- Standardization of spirometry 2019 update. An official American thoracic society and european respiratory society technical statement.Am J Respir Crit Care Med. 2019; 200: e70-e88https://doi.org/10.1164/rccm.201908-1590ST
Minitab, LLC (2020). Getting started with Minitab 20. www.minitab.com.
- Adherence to nebulised therapies in adolescents with cystic fibrosis is best on week-days during school term-time.J Cyst Fibros. 2013; 12: 440-444https://doi.org/10.1016/j.jcf.2012.12.012
- School nurse asthma program reduces healthcare utilization in children with persistent asthma.J Asthma. 2018; 55: 1131-1137https://doi.org/10.1080/02770903.2017.1396473
- Effects of a supervised, outpatient exercise and physiotherapy programme in children with cystic fibrosis.Pediatr Pulmonol. 2012; 47: 1235-1241https://doi.org/10.1002/ppul.22587
- Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis.Eur Respir J. 2012; 40: 61-66https://doi.org/10.1183/09031936.00159111
- Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis.Thorax. 2011; 66: 680-685https://doi.org/10.1136/thx.2011.161117
- Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registry.Eur Respir J. 2014; 43: 125-133https://doi.org/10.1183/09031936.00166412
- Progressive damage on high resolution computed tomography despite stable lung function in cystic fibrosis.Eur Respir J. 2004; 23: 93-97https://doi.org/10.1183/09031936.03.00006603
- Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease.Eur Respir Rev. 2020; 29190112https://doi.org/10.1183/16000617.0112-2019
- The demographics of adverse outcomes in cystic fibrosis.Pediatr Pulmonol. 2019; 54 (Suppl 3): S74-S83https://doi.org/10.1002/ppul.24434
- Objective measurement of adherence to out-patient airway clearance therapy by high-frequency chest wall compression in cystic fibrosis.Respir Care. 2017; 62: 920-927https://doi.org/10.4187/respcare.05349
Published online: January 24, 2023
Accepted: January 12, 2023
Received in revised form: January 11, 2023
Received: October 14, 2022
Publication stageIn Press Corrected Proof
© 2023 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.